A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.
about
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
A first-in-human phase I study ...... ral Src/ABL inhibitor AZD0424.
@en
A first-in-human phase I study ...... ral Src/ABL inhibitor AZD0424.
@nl
type
label
A first-in-human phase I study ...... ral Src/ABL inhibitor AZD0424.
@en
A first-in-human phase I study ...... ral Src/ABL inhibitor AZD0424.
@nl
prefLabel
A first-in-human phase I study ...... ral Src/ABL inhibitor AZD0424.
@en
A first-in-human phase I study ...... ral Src/ABL inhibitor AZD0424.
@nl
P2093
P2860
P356
P1476
A first-in-human phase I study ...... ral Src/ABL inhibitor AZD0424.
@en
P2093
Claire Barton
Helen Turner
Lisa K Folkes
Mark R Middleton
Michael R L Stratford
Paul Jones
Richard Eastell
Richard H Wilson
Sally Clive
Sarah Halford
P2860
P2888
P304
P356
10.1038/BJC.2017.484
P407
P577
2018-02-13T00:00:00Z